Andy Acker - Empty Rooms: Investing in Biotech at Janus Henderson (Capital Allocators, EP.274)

Episode Summary

Executive Summary: Andy Acker argues biotech is a high-opportunity, high-volatility sector where scientific innovation has accelerated dramatically, but market prices often overreact. He outlines a disciplined framework centered on 90/90 clinical and commercial risk, deep scientific research, management quality, and valuation discipline, while highlighting green shoots from better data, financing, M&A, and gene-based therapies.

Main Topics: Path into healthcare investing (Priority: 4/5): Acker explains how a family of physicians, a biochemistry background, and early investing experience led him from pre-med to Morgan Stanley and then Janus Henderson, where he has spent more than two decades investing in healthcare. Scientific innovation and biotech progress (Priority: 5/5): He describes how advances in genomics, vaccine development, precision oncology, RNA therapies, cell therapies, and antibody-drug conjugates have transformed the investable landscape and created real therapeutic breakthroughs. The 90/90 rule: clinical and commercial risk (Priority: 5/5): Acker’s core framework emphasizes that roughly 90% of drugs fail in clinical development and that Wall Street is wrong about 90% of launch forecasts, making stock selection dependent on identifying outliers better than the market. Biotech volatility, market psychology, and valuation dislocations (Priority: 5/5): He argues biotech stocks move far more than underlying business value, creating opportunities during bear markets when high-quality companies trade at deep discounts or below cash. Investment process and portfolio construction (Priority: 4/5): The team combines scientific diligence, management evaluation, financial modeling, discounted cash flow valuation, position sizing, and sector diversification to manage binary event risk. Private crossover investing and early visibility (Priority: 3/5): Janus Henderson invests in private biotech names near IPO timing to access innovation earlier and understand both potential winners and future disruptors to public holdings. Current opportunities, risks, and green shoots (Priority: 5/5): Acker highlights gene therapies, NASH, and obesity as major themes, while noting drug pricing, reimbursement, and patent cliffs as key risks; he sees improving data, financing, and M&A as signs of a bottom.

Key Arguments: Biotech has become far more scientifically productive, with genome sequencing, mRNA, gene therapy, and cell therapy opening new commercial opportunities. The sector’s binary nature means investors must be right on both science and commercialization, not just on the underlying idea. Clinical development is a 90% failure business; success requires the right drug, patient population, dose, delivery, trial design, and timing. Commercial launches are also highly uncertain because physicians, patients, and payers must all be aligned for uptake. Market volatility often creates mispricings because stock prices can fall far more than intrinsic value changes. Management quality can materially change outcomes by improving development choices, fixing weak programs, or pursuing better alternatives. The bear market created rare value, including companies trading below cash and early commercial names priced as if pipelines were worthless. Long-term outperformance comes from repeatedly identifying companies with better-than-consensus odds of success or failure. Private investing provides early access to innovation and helps identify future public winners and competitive threats. Gene-based therapies, NASH treatments, and obesity drugs represent some of the biggest unmet medical needs and market opportunities. Regulatory and policy risk, especially drug pricing, matters, but the Inflation Reduction Act is viewed as more manageable than feared. Signs of a turn include good clinical data being rewarded, successful financing, and rising M&A driven by patent expirations and cash-rich pharma buyers.

Data Points: Human Genome Project timeline/cost: 13 years and $3 billion - Acker contrasts the original genome project with today’s much faster and cheaper sequencing. Current genome sequencing speed/cost: Hours and hundreds of dollars - Shows dramatic progress in genomics since the early 2000s. COVID-19 vaccine development speed: 2 highly effective vaccines in 10 months - Used as an example of accelerated biotech innovation during the pandemic. New medicines approved in the last 5 years: 256 - Illustrates the pace of drug innovation. Increase vs. 10 years ago: Up over 100% - Compares recent approval volume to the prior decade. Drugs entering human testing that reach market: 10% - Core statistic behind the 90/90 rule for clinical development. Average phase 3 success rate: About 50% - Emphasizes the binary nature of pivotal trials. Typical stock reaction to clinical success/failure: Up 50%-100%+ or down 50%-90% in a day - Describes event-driven volatility around trial outcomes. Biotech bear markets in 16 years: 11 declines of at least 20% - Shows repeated sector volatility since the XBI’s creation. Biotech drawdown Feb 2021 to Jun 2022: -64% absolute; -75% vs healthcare - One of the worst biotech bear markets in history. Development-stage biotech value decline: -70% over 18 months - Highlights severity of the downturn. Companies trading below cash: About 200 - Shows extreme valuation dislocation in the sector. Discount to cash: 50%-80% below cash in some cases - Illustrates market pricing as if assets were worth less than liquidation value. Top biotech/healthcare position sizing: Top 10 stocks = 30%-35% of portfolio - Portfolio concentration at the top of the healthcare strategy. Maximum single-event risk in healthcare strategy: 1% (100 bps) - Risk limit for one binary event. Maximum single-event risk in biotech strategy: 2% (200 bps) - Higher but still bounded risk tolerance for biotech. Biotech’s contribution to new medicines: Over 60% - Small and mid-cap biotech companies account for most new medicines reaching market. Private investment success rate: More than two-thirds of the time - Historical success rate in crossover private investments. Obesity prevalence: 100 million in the U.S.; 500 million worldwide - Frames obesity as a major unmet medical need. NASH trial result: 77% resolution after six months - Example of promising efficacy in fatty liver disease. Sickel cell disease market example: Oxbryta annualizing around $300 million in sales - Illustrates a commercial product in hematology. Global Blood Therapeutics acquisition price: Over $5 billion - Pfizer’s buyout of a company with a promising pipeline. Global Blood Therapeutics earlier trading value: Closer to $2 billion - Shows value creation from management persistence and pipeline development. Sarepta stock reaction to failed phase 2: Down 50% in a day - Example of a painful setback that later still left room for upside. Patients not filling prescriptions due to cost: About one-third - Used to explain why drug pricing is a major industry/political risk. Medicare out-of-pocket cap under IRA: $2,000 per year - Acker views this provision as positive for seniors. Estimated pharma cash by end of 2022: $500 billion - Supports the case for increased M&A activity. Pfizer acquisition need by 2030: $25 billion of revenue - Example of large pharma needing acquisitions to replace lost sales.

Pivotal Quotes: "90% of the products that begin human clinical testing never make it all the way to market." — Andy Acker: Explains the first half of his 90/90 framework for drug development risk. "Our view is that not every drug is average." — Andy Acker: Describes why deep fundamental research can identify drugs with better-than-market odds of success or failure. "We want to be able to obsolete our own product and make any, you know, if anyone's going to do better than this product, we want it to be us." — Andy Acker: Illustrates how strong management can create value by continuing to innovate after initial success.

Implications: Biotech remains a specialist arena where research depth, valuation discipline, and risk control can generate alpha. The recent reset plus better science, financing, and M&A may create a more favorable setup ahead.